

## Efficient Differentiation of Human Pluripotent Stem Cells to Endothelial Progenitors via Small-Molecule Activation of WNT Signaling

Xiaojun Lian,<sup>1,2,3</sup> Xiaoping Bao,<sup>1,2</sup> Abraham Al-Ahmad,<sup>1</sup> Jialu Liu,<sup>1</sup> Yue Wu,<sup>1</sup> Wentao Dong,<sup>1</sup> Kaitlin K. Dunn,<sup>1</sup> Eric V. Shusta,<sup>1</sup> and Sean P. Palecek<sup>1,\*</sup>

<sup>1</sup>Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA

<sup>2</sup>Co-first author

<sup>3</sup>Present address: Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm 17177, Sweden

\*Correspondence: [palecek@engr.wisc.edu](mailto:palecek@engr.wisc.edu)

<http://dx.doi.org/10.1016/j.stemcr.2014.09.005>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

### SUMMARY

Human pluripotent stem cell (hPSC)-derived endothelial cells and their progenitors may provide the means for vascularization of tissue-engineered constructs and can serve as models to study vascular development and disease. Here, we report a method to efficiently produce endothelial cells from hPSCs via GSK3 inhibition and culture in defined media to direct hPSC differentiation to CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors. Exogenous vascular endothelial growth factor (VEGF) treatment was dispensable, and endothelial progenitor differentiation was  $\beta$ -catenin dependent. Furthermore, by clonal analysis, we showed that CD34<sup>+</sup>CD31<sup>+</sup>CD117<sup>+</sup>TIE-2<sup>+</sup> endothelial progenitors were multipotent, capable of differentiating into calponin-expressing smooth muscle cells and CD31<sup>+</sup>CD144<sup>+</sup>vWF<sup>+</sup>I-CAM1<sup>+</sup> endothelial cells. These endothelial cells were capable of 20 population doublings, formed tube-like structures, imported acetylated low-density lipoprotein, and maintained a dynamic barrier function. This study provides a rapid and efficient method for production of hPSC-derived endothelial progenitors and endothelial cells and identifies WNT/ $\beta$ -catenin signaling as a primary regulator for generating vascular cells from hPSCs.

### INTRODUCTION

Human pluripotent stem cells (hPSCs) offer unprecedented opportunities to study the earliest stages of human development *in vitro*, to model human disease, to perform drug tests in culture, and to develop unlimited new sources of cells for possible therapeutic applications. To realize this potential, it is essential to be able to control hPSC differentiation to somatic lineages with high efficiency and reproducibility in a scalable and inexpensive manner (Ashton et al., 2011; Burridge et al., 2012; Kinney et al., 2014; Murry and Keller, 2008).

Functional human endothelial cells differentiated from hPSCs could be beneficial for many potential clinical applications (Burridge et al., 2012; Kaupisch et al., 2012; Levenberg et al., 2002; van der Meer et al., 2013), including engineering new blood vessels, endothelial cell transplantation into the heart for myocardial regeneration (Robey et al., 2008), and induction of angiogenesis for treatment of regional ischemia (Liu et al., 2014). Endothelial cell dysfunction is also associated with many diseases, including Alzheimer's disease, stroke, multiple sclerosis, and atherosclerosis (Boyle et al., 1997; Weiss et al., 2009). hPSC-derived endothelial progenitors and endothelial cells may provide building blocks for the establishment of *in vitro* disease models for screening and development of drugs to treat these diseases. Functionality of hPSC-derived endothelial cells has been shown using *in vitro* cell culture platforms and *in vivo* animal models (Adams et al., 2013;

Kusuma et al., 2013; Orlova et al., 2014; Samuel et al., 2013; Wang et al., 2007). Similar to other somatic cells derived from hPSCs, differentiated CD31<sup>+</sup> endothelial cells exhibited functional heterogeneity (Rufaihah et al., 2013). Previously reported studies of hPSC differentiation to endothelial cells have demonstrated that Activin/Nodal/transforming growth factor  $\beta$  (TGF- $\beta$ ), bone morphogenetic protein (BMP), vascular endothelial growth factor (VEGF), and microRNA-21 signaling promote this differentiation (Di Bernardini et al., 2013; James et al., 2010; Kane et al., 2010; Lu et al., 2007; Marchand et al., 2014; Rufaihah et al., 2011; Wang et al., 2004; Zambidis et al., 2005). In addition, mechanical shear stress also promoted embryonic stem cell-derived endothelial phenotypes (Wolfe and Ahsan, 2013).

During murine embryogenesis, hemangioblasts, which can differentiate into multipotent hematopoietic stem cells and endothelial progenitors, are derived from a subpopulation of mesoderm that coexpresses brachyury and KDR (Huber et al., 2004). Similar blast colony-forming cells were also isolated from mouse embryonic stem cell aggregates in the presence of cytokines (Kennedy et al., 1997). When cocultured with OP9 stromal cells, hPSCs differentiated to mesodermal progenitors with the capacity to form blast or hemangioblast colonies in response to fibroblast growth factor 2 (FGF2) (Vodyanik et al., 2010). As another approach, hPSCs cultured as embryoid bodies were exposed to a growth factor cocktail containing activin A, BMP4, FGF2, and VEGF to induce differentiation to



CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors (Costa et al., 2013; Levenberg et al., 2002; Song et al., 2013). The CD34<sup>+</sup>CD31<sup>+</sup> vascular progenitor population generated endothelial cells and smooth muscle cells in the proper culture environments (Bai et al., 2010). TGF- $\beta$  signaling enhanced smooth muscle cell differentiation from these endothelial progenitors, whereas the TGF- $\beta$  signaling inhibitor SB431542 promoted endothelial cell generation and expansion (James et al., 2010). Global gene transcription analysis demonstrated low variability between endothelial cells (ECs) differentiated from multiple lines of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in the presence of these cytokines (White et al., 2013). Although prior studies have demonstrated differentiation of hPSCs to endothelial progenitors, and subsequently to ECs and smooth muscle cells, by applying growth factors from different signaling pathways, it is largely unknown whether these distinct differentiation protocols produce identical endothelial cells and their progenitors, and which developmental signaling mechanisms are necessary and sufficient to specify these differentiation fates.

Here, we describe a simple and efficient method for the conversion of hPSCs to CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors. Appropriate temporal activation of regulators of WNT signaling alone, in the absence of exogenous FGF2 and VEGF signaling, was sufficient to drive multiple hPSC lines to differentiate to greater than 50% CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors. However, endogenous MEK signaling was required for hPSC differentiation to endothelial progenitors because MEK inhibitor treatment substantially diminished the yield of CD34<sup>+</sup>CD31<sup>+</sup> cells. These hPSC-derived endothelial progenitors were further enriched to 99% purity with a single step of CD34-based magnetic separation. Single-cell clonal differentiation assays revealed that CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors generated by WNT pathway activation were bipotent and could differentiate to functional endothelial cells and smooth muscle cells.

## RESULTS

### GSK3 Inhibition Is Sufficient to Induce hPSC Differentiation to Endothelial Progenitors in the Absence of Exogenous Growth Factors


We previously demonstrated that temporal modulation of canonical WNT signaling is sufficient to generate functional cardiomyocytes at high yield and purity (Lian et al., 2012, 2013b). In that study, a virtually pure population of brachyury<sup>+</sup> cells was generated within 24 hr after treatment of undifferentiated hPSCs with a GSK3 inhibitor. In order to direct these brachyury<sup>+</sup> cells to a cardiomyocyte fate, we then inhibited canonical WNT signaling by

either expression of  $\beta$ -catenin small hairpin RNA (shRNA) or treatment with small-molecule inhibitors of WNT signaling at the proper corresponding time points. To assess whether these GSK3 inhibitor-induced brachyury<sup>+</sup> mesoderm progenitors also have the potential to differentiate to endothelial progenitors, we treated 19-9-11 iPSCs with the GSK3 inhibitor CHIR99021 and subsequently cultured the cells in StemPro-34 medium supplemented with VEGF, both of which have been reported to stimulate vascular cell differentiation of hPSCs (Grigoriadis et al., 2010) (Figure 1A). After optimizing the concentrations and timing of application of various components, the differentiation protocol consisted of two phases. Phase I generated brachyury<sup>+</sup> cells by treatment of undifferentiated hPSCs with CHIR99021 for 2 days, whereas phase II directed the brachyury<sup>+</sup> progenitors to CD34<sup>+</sup>CD31<sup>+</sup> cells by culture in StemPro-34 supplemented with VEGF for 3 days. We found that without CHIR99021 treatment, very few CD34<sup>+</sup>CD31<sup>+</sup> cells were generated from human iPSCs, even in the presence of VEGF (Figure 1B). However, treatment of the human iPSCs with CHIR99021 generated more than 20% CD34<sup>+</sup>CD31<sup>+</sup> cells. Interestingly, VEGF treatment did not significantly increase the yield of CD34<sup>+</sup>CD31<sup>+</sup> cells in this differentiation system (Figure 1B). However, in the presence of sunitinib, which inhibits several receptor tyrosine kinases including VEGFR, very few CD34<sup>+</sup>CD31<sup>+</sup> cells were generated, suggesting that endogenous VEGF signaling is required for endothelial progenitor differentiation stimulated by CHIR99021 treatment (Figure 1C). Because of these observations, we did not include exogenous VEGF in subsequent differentiation experiments. In addition, this differentiation protocol primarily generated CD34<sup>+</sup>CD31<sup>+</sup> cells and produced very few CD34<sup>+</sup>CD31<sup>-</sup> or CD34<sup>+</sup>CD31<sup>-</sup> cells (Figure 1B).

We further tested the concentration dependence of CHIR99021 for inducing CD31<sup>+</sup>CD34<sup>+</sup> endothelial progenitor differentiation and found that 6–10  $\mu$ M generated 25% endothelial progenitors (Figure 1D). Similar results were obtained in the H1 hESC line (Figure S1 available online). These CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors also expressed CD144 (VE-cadherin), but not CD45, indicating these cells were not in hematopoietic lineages (Figure S1). These results illustrate that induction of WNT signaling via the GSK3 inhibitor CHIR99021 permitted subsequent differentiation of hPSCs to CD34<sup>+</sup>CD31<sup>+</sup> cells, and that exogenous VEGF was not required.

### Endothelial Progenitor Differentiation Induced by GSK3 Inhibitors in hPSCs Is $\beta$ -Catenin Dependent

Selectivity is a general concern with the use of chemical inhibitors. We tested other GSK3 inhibitors, BIO-acetoxime and CHIR98014, and found that both also effectively induced endothelial progenitor differentiation to a similar



### Figure 1. Derivation of CD34<sup>+</sup>CD31<sup>+</sup> Cells from hPSCs via GSK3 Inhibitor Treatment

(A) Schematic of the protocol for differentiation of hPSCs to CD34<sup>+</sup>CD31<sup>+</sup> cells via treatment with a GSK3 inhibitor.

(B) 19-9-11 iPSCs were cultured on Matrigel for 2 days in LaSR basal medium with or without 6 µM CH followed by another 3 days in StemPro-34 medium with or without VEGF.


(C) 19-9-11 iPSCs were cultured on Matrigel in LaSR basal medium with 6 µM CH for 2 days followed by another 3 days in StemPro-34 medium with 1 µM sunitinib at indicated times.

(D) 19-9-11 iPSCs were cultured on Matrigel in LaSR basal medium with different concentrations of CH for 2 days followed by another 3 days in StemPro-34 medium. All flow cytometric analyses of CD34 and CD31 expression were performed after 5 days of differentiation. Data are represented as mean ± SEM of at least three independent replicates.

See also Figure S1.

extent as CHIR99021 in the absence of VEGF treatment (Figure 2A). These small molecule compounds have distinct chemical structures, reducing the likelihood of shared off-target effects. However, GSK3 inhibition can affect multiple signaling pathways, including the desired activation of canonical WNT signaling by stabilizing  $\beta$ -catenin protein. In order to evaluate the role of  $\beta$ -catenin in GSK3 inhibitor-induced hPSC endothelial differentiation, we generated an iPSC line (19-9-11 ishcat-1) expressing  $\beta$ -catenin shRNA under the control of a tet-regulated inducible promoter. Upon doxycycline (dox) addition, the shRNA efficiently downregulated  $\beta$ -catenin expression (Figure 2B). We used this cell line to examine the stage-specific roles of  $\beta$ -catenin during monolayer endothelial differentiation stimulated by GSK3 inhibition. Undifferentiated

19-9-11 ishcat-1 iPSCs were treated with 6 µM CHIR99021 for 48 hr followed by another 3 days culture in StemPro-34 medium. Dox was added at various time points between day 0 and day 4, and endothelial progenitor differentiation was assessed at day 5 as the percentage of CD34<sup>+</sup>CD31<sup>+</sup> cells. We found that WNT/ $\beta$ -catenin signaling was essential for endothelial induction by CHIR99021 because  $\beta$ -catenin knockdown at day 0 did not generate CD34<sup>+</sup>CD31<sup>+</sup> cells. We previously showed that  $\beta$ -catenin is essential for *brachyury* expression after hPSC treatment with GSK3 inhibitors (Lian et al., 2012). We reasoned that abrogation of the CD34<sup>+</sup>CD31<sup>+</sup> population by  $\beta$ -catenin knockdown at day 0 was due to blocking differentiation of hPSCs to brachyury-expressing mesoderm progenitors. We profiled the expression of brachyury



**Figure 2. CD34<sup>+</sup>CD31<sup>+</sup> Endothelial Progenitor Differentiation Induced by GSK3 Inhibitors in hPSCs Is β-Catenin Dependent**

(A) 19-9-11 iPSCs were cultured on Matrigel in LaSR basal medium containing DMSO, 0.6 μM CHIR98014, 0.6 μM BIO-acetoxime, or 6 μM CHIR99021 for 2 days before culture in StemPro-34 medium for 3 days. At day 5, the percentage of CD34<sup>+</sup>CD31<sup>+</sup> cells in culture was assessed by flow cytometry.

(B) 19-9-11 iscramble and 19-9-11 ishcat cells were cultured in mTeSR1 containing 2 μg/ml doxycycline. After 3 days, mRNA was collected and β-catenin expression evaluated by qPCR. #p < 0.005, ishcat versus iscramble; t test.

(C) 19-9-11 ishcat cells were cultured in LaSR basal medium containing 6 μM CHIR99021 for 2 days before exposure to StemPro-34 medium for 3 days, with 2 μg/ml dox addition at the indicated times. Five days after initiation of differentiation, cells were analyzed for CD34 and CD31 expression by flow cytometry.

(D) Western blot analysis of phospho-ERK (p-ERK) and ERK in 19-9-11 cells after 24 hr in LaSR basal medium supplemented with PD0325901 at the indicated concentrations.

(E) 19-9-11 cells were cultured in LaSR basal medium containing 6 μM CHIR99021 for 2 days before exposure to StemPro-34 medium for 3 days, with 1 μM PD0325901 addition at the indicated times. Five days after initiation of differentiation, cells were analyzed for CD34 and CD31 expression by flow cytometry. Data are represented as mean ± SEM of at least three independent replicates.


See also Figure S2.

during the 5 day differentiation and found a virtually pure population of brachyury<sup>+</sup> cells generated by day 2 in the absence of dox. The presence of dox treatment, however, abolished brachyury expression (Figure S2). Importantly, depletion of β-catenin expression at time points after brachyury expression was detected also reduced the percentage of CD34<sup>+</sup>CD31<sup>+</sup> cells generated (Figure 2C), indicating β-catenin might also be involved in differentiation of mesendoderm to CD34<sup>+</sup>CD31<sup>+</sup> cells. Because of the important role of FGF2 signaling on brachyury<sup>+</sup> cell differentiation from hPSCs (Yu et al., 2011) and the mesodermal origin of endothelial progenitors, we used an MEK inhibitor to study the role of MEK/ERK signaling on CD34<sup>+</sup>CD31<sup>+</sup> cell differentiation. We found that 1 μM of MEK inhibitor PD0325901, which effectively blocked ERK phosphoryla-

tion (Figure 2D), substantially diminished CD34<sup>+</sup>CD31<sup>+</sup> cell differentiation, suggesting that endogenous MEK/ERK signaling promotes endothelial progenitor differentiation (Figure 2E).

### Differentiation Medium and Cell Density Dependence of GSK3 Inhibitor-Induced Endothelial Progenitor Differentiation

We have shown that hPSCs can be differentiated to CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors by 2 days (phase I) of culture in an optimized defined medium supplemented with GSK3 inhibitors and another 3 days (phase II) in StemPro-34 medium. In order to streamline the differentiation process, we tested whether a single basal medium could support endothelial progenitor differentiation



**Figure 3. Differentiation Medium and Cell Density Dependence of GSK3 Inhibitor-Induced Endothelial Progenitor Differentiation**

(A) Schematic of the protocol for defined, growth factor-free differentiation of hPSCs to endothelial progenitors in a single differentiation medium.

(B) 19-9-11 iPSCs were cultured as indicated in (A), with different basal differentiation media. At day 5, cells were analyzed for CD34 and CD31 expression by flow cytometry.  $p = 0.02$ , LaSR basal versus StemPro 34;  $t$  test.

(C-E) 19-9-11 iPSCs were differentiated as described in (A) using LaSR basal medium, with different day -3 cell seeding densities. At day 5, cells were analyzed for CD34 and CD31 expression by flow cytometry (C). Data are represented as mean  $\pm$  SEM of at least three independent replicates. (D) shows a representative CD34/CD31 flow plot from a seeding density of 0.05 million cells/cm<sup>2</sup>, and (E) shows a representative flow cytometry analysis of OCT4 expression in 19-9-11 cells at day 0 after expansion in mTeSR for 3 days.

(Figure 3A). We examined 13 different media supplemented with CHIR99021 for 2 days (phase I) followed by 3 additional days in the same basal medium lacking exogenous growth factors or chemical inhibitors (phase II). We found that advanced DMEM/F12 supplemented with ascorbic acid, which we termed LaSR basal medium, was the most efficient for endothelial progenitor differentiation, resulting in 25% CD34<sup>+</sup>CD31<sup>+</sup> cells in 5 days

(Figure 3B). These results indicated the importance of basal medium composition in endothelial progenitor differentiation, with some media (e.g., RPMI/B27 and EC medium containing serum) not supporting differentiation to any detectable CD34<sup>+</sup>CD31<sup>+</sup> cells (Figure 3B).

On the basis of the knowledge that initial cell density affects hPSC differentiation fates to lineages such as cardiomyocytes, epithelial progenitors, and pancreatic cells



(Gage et al., 2013; Lian et al., 2013a; Selekman et al., 2013; Takizawa-Shirasawa et al., 2013), we quantitatively assessed the effect of initial cell seeding density on endothelial progenitor differentiation efficiency. Singularized hPSCs were seeded at densities ranging from 12,000 to 300,000 cells per  $\text{cm}^2$  and then expanded in mTeSR1 for 3 days before transition to LaSR basal medium supplemented with CHIR99021 for 2 days and another 3 days in LaSR basal medium lacking CHIR99021. The optimal seeding density was 50,000 cells per  $\text{cm}^2$  at day -3, which resulted in 325,000 cells per  $\text{cm}^2$  at day 0 (Figure 3C). At day 5, 55% of cells seeded at this density expressed CD34 and CD31 (Figures 3C and 3D). We performed fluorescence-activated cell sorting (FACS) analysis of OCT4 expression of day 0 cells and found that more than 99.5% of the cells were OCT4<sup>+</sup>, suggesting that hPSCs were pluripotent before addition of CH (Figure 3E).

#### CD34<sup>+</sup>CD31<sup>+</sup> Endothelial Progenitors Are Multipotent

Molecular analysis of endothelial progenitor differentiation from hPSCs revealed dynamic changes in gene expression, with downregulation of the pluripotency markers *SOX2* and *OCT4*, and induction of the primitive streak-like genes *T* (Nakanishi et al., 2009) and *MIXL1* (Davis et al., 2008) in the first 24 hr after CH addition (Figure 4A). Expression of the endothelial progenitor markers *CD34* and *CD31* was detected at day 4 and increased at day 5 (Figure 4A). Western blot analysis of protein expression revealed decreasing OCT4 expression during the first 2 days of differentiation, and brachyury induction on days 1 and 2 followed by downregulation on day 3. The endothelial marker VE-cadherin was only detected after 5 days of differentiation (Figure 4B). Immunofluorescent analysis revealed the expression of CD34, CD31, and VE-cadherin on day 5 (Figure 4C). Ten days after differentiation without passaging, however, the expression of CD34 diminished, whereas the cells retained expression of CD31<sup>+</sup> and VE-cadherin (Figure 4C).


To study the multipotent nature of the transient population of CD34<sup>+</sup> cells, we first enriched the day 5 differentiation culture to 99% purity of CD34<sup>+</sup> cells by magnetic-activated cell sorting (MACS) (Figure 5A). We also enriched the day 5 differentiation cultures of additional hESC lines (H13, H14) and human iPSC lines (19-9-7 and 6-9-9) to more than 99% purity of CD34<sup>+</sup> cells (Figures S3A–S3D). The sorted CD34<sup>+</sup> putative endothelial progenitors were plated on Matrigel-coated 48-well plates at a density of one cell per well in a combined medium (50% smooth muscle and 50% endothelial medium). After 10 days of culture, the differentiation populations from ten different single-cell clones contained both VE-cadherin<sup>+</sup> von Willebrand factor (vWF)<sup>+</sup> cells and Calponin<sup>+</sup> SMMHC<sup>+</sup> (Smooth muscle myosin heavy chain) cells, including some cells ex-

pressing both endothelial and smooth muscle markers (Figure 5B; Figures S3E and S3F), thereby demonstrating that single CD34<sup>+</sup> endothelial progenitors generated from hPSCs were multipotent. In addition, when the sorted CD34<sup>+</sup> clones were cultured in endothelial or smooth muscle medium rather than the mixed medium, they generated relatively pure populations of endothelial cells and smooth muscle cells, respectively (Figures 5C and 5D). The hPSC-derived endothelial progenitors expressed C-KIT (CD117), KDR (VEGFR2), TIE-2, CD31, CD34, CD144, but did not express vWF or intercellular adhesion molecule 1 (ICAM-1) (Figure 6). We also quantified TIE-2, CD117, KDR, and ICAM-1 expression with flow cytometry (Figure S4), and results were consistent with immunostaining experiments. The day 15 endothelial cells expressed CD31, CD144, vWF, ICAM-1, and KDR, but did not express CD117, CD34, or TIE-2 (Figure 6).

#### Characterization of Endothelial Cells Derived from hPSCs

To study the intrinsic properties of endothelial cells differentiated from hPSCs by GSK3 inhibition and culture in LaSR basal medium, we cultivated the purified CD34<sup>+</sup> cells in endothelial medium on laminin-coated plates and found that the resulting CD34<sup>+</sup>CD31<sup>+</sup>vWF<sup>+</sup>CD144<sup>+</sup> endothelial cells were capable of approximately 20 population doublings over 2 months, generating more than 1 million cells from a single endothelial cell (Figure 7A). After 2 months in culture, the cells still expressed CD31 and VE-cadherin based on immunostaining (Figure 7B). Flow cytometry analysis also showed that more than 99% of cells expressed CD31 and VE-cadherin after 60 days in culture (Figure S5). Furthermore, upon treatment with exogenous VEGF, the CD144<sup>+</sup> cells formed vascular tubes in Matrigel matrix (Figure 7C) and were capable of acetylated low-density lipoprotein (AcLDL) uptake, indicative of endothelial function (Figure 7D). The endothelium also responds to inflammatory mediators, such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), by upregulating adhesion molecules including ICAM-1, which has been implicated in the capture of circulating leukocytes. Although unstimulated endothelial cells expressed low levels of ICAM-1, TNF- $\alpha$  treatment greatly increased the expression of ICAM-1 in the hPSC-derived endothelial cells (Figure 7E).

To characterize the barrier phenotype of the hPSC-derived endothelial cells, we measured the transendothelial electrical resistance (TEER) and transport of fluorescent 40 kDa dextran across a monolayer of differentiated endothelial cells. VEGF treatment induced a sustained decrease in TEER and an increase in dextran permeability. However, treatment of endothelial cells with the cAMP analog 8-pCPT-2'-O-Me-cAMP (o-Me) decreased dextran permeability and increased TEER (Figures 7F and 7G).




**Figure 4. Molecular Analysis of Endothelial Progenitors Differentiated from hPSCs**

19-9-11 iPSCs were differentiated as illustrated in Figure 3A using LaSR basal medium. At different time points, developmental gene or protein expression was assessed by quantitative RT-PCR (A) or western blot (B). Data are represented as mean  $\pm$  SEM of at least three independent replicates. At 5 days or 10 days postdifferentiation, immunostaining for CD34, CD31, and VE-cadherin was performed (C).

## DISCUSSION

Prior reports of differentiating hPSCs to endothelial cells required the addition of expensive growth factors and/or

undefined serum to direct endothelial development, and these methods generated heterogeneous cell mixtures typically containing less than 10% endothelial cells. Here, we show that small-molecule activation of canonical WNT



### Figure 5. CD34<sup>+</sup>CD31<sup>+</sup> Endothelial Progenitors Are Multipotent

19-9-11 iPSCs were differentiated as illustrated in Figure 3A using LaSR basal medium.

(A) At day 5, CD34<sup>+</sup> cells were enriched with the EasySep Human CD34 Positive Selection Kit and purification quantified by flow cytometry for CD34 expression.

(B–D) Sorted CD34<sup>+</sup> cells were cultured in a combined medium (B), a smooth muscle medium (C), or an endothelial medium (D) at a density of one cell per well in a 48-well plate for another 10 days. Sample immunofluorescence images for smooth muscle and endothelial markers were shown. In (B), arrows point to SMMHC<sup>+</sup>VE-cadherin<sup>−</sup> cells. See also Figure S3.


signaling via GSK3 inhibition, in the absence of exogenous growth factors, is sufficient to generate high yields of CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors from hPSCs. Prior to this study, endothelial progenitors have not been isolated from hPSCs under defined conditions, and the mechanisms by which developmental signaling pathways regulate endothelial progenitor commitment remained largely unknown (Slukvin, 2013). With a doxycycline-inducible shRNA knockdown of the WNT pathway modulator  *$\beta$ -catenin*, we identified that  *$\beta$ -catenin* is required for CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitor generation from hPSCs following GSK3 inhibition. Furthermore, although previous reports required more than 10 days to generate CD34<sup>+</sup>CD31<sup>+</sup> cells, this small molecule differentiation approach accelerates developmental timing and converts hPSCs to greater than 50% CD34<sup>+</sup>CD31<sup>+</sup> cells in 19-9-11 iPSCs in 5 days. This protocol produced more than 99% pure populations of CD34<sup>+</sup>CD31<sup>+</sup> cells from six different hPSC lines following a single magnetic affinity separation.

GSK3 inhibition has been shown to be a potent inducer of mesendoderm lineage commitment in hPSCs (Tan et al., 2013). The WNT pathway exhibits crosstalk with a variety of other developmental signaling networks, including

TGF- $\beta$  superfamily (Cai et al., 2013), FGF (Stulberg et al., 2012), Notch (Wang et al., 2013), Hippo (Hergovich and Hemmings, 2010), and retinoic acid signaling (Chanda et al., 2013). The necessity of  *$\beta$ -catenin* in generating CD34<sup>+</sup>CD31<sup>+</sup> cells indicates a direct role of canonical WNT signaling in endothelial progenitor differentiation, whereas the diminished yield of CD34<sup>+</sup>CD31<sup>+</sup> cells in the presence of MEK and receptor tyrosine kinase inhibitors suggests endogenous pathways also mediate endothelial progenitor differentiation. Thus, canonical WNT signaling is not the only pathway required for endothelial progenitor specification, but it may act as a master regulator to orchestrate signaling that leads to endothelial progenitor differentiation.

We have previously reported a method to differentiate hPSCs to a relatively pure population of cardiomyocytes by dynamic modulation of canonical WNT signaling using small-molecule GSK3 inhibitors and Porcupine inhibitors in a RPMI/B27 medium lacking insulin (Lian et al., 2012, 2013a). This protocol uses WNT pathway activation to direct mesendoderm differentiation, followed by WNT pathway inhibition to specify cardiac mesoderm and cardiomyocyte fates. Although the small molecule cardiomyocyte and endothelial progenitor differentiation protocols





**Figure 6. Day 5 Endothelial Progenitors Differ from Day 15 Endothelial Cells in Marker Expression**

19-9-11 iPSCs were differentiated as illustrated in Figure 3A using LaSR basal medium, and unsorted day 5 progenitor cells and day 15 endothelial cells were immunostained for developmental markers as indicated. See also Figure S4.

result in optimal cell yields in distinct defined basal media, both progress through mesodermal progenitors via GSK3 inhibition. These mesodermal progenitors can be directed to spontaneously contracting cardiomyocytes via WNT inhibition, while permitting endogenous canonical WNT signaling yields a population enriched in endothelial progenitors. Together, these results demonstrate the concept of chemically guiding differentiation to distinct cell types via different patterns of modulation of master regulators of cell fates. This paradigm may represent a promising general approach to efficiently produce cells and tissues from stem cell sources in a defined manner.


Interestingly, the WNT pathway-induced endothelial progenitor differentiation protocol primarily generates CD34 and CD31 double-positive cells, as opposed to other methods using BMP4, which produce a mixture of CD34<sup>+</sup>CD31<sup>-</sup>, CD34<sup>+</sup>CD31<sup>+</sup>, CD34<sup>-</sup>CD31<sup>+</sup> cells (Bai et al., 2010; Song et al., 2013). The CD34<sup>+</sup>CD31<sup>+</sup> endothelial progenitors may be more amenable to large-scale expansion. Furthermore, these endothelial progenitors can be further directed to endothelial cells or smooth

muscle cells by culture in the appropriate inductive media. Purified CD31<sup>+</sup>VE-cadherin<sup>+</sup>vWF<sup>+</sup>CD34<sup>-</sup> endothelial cells were expanded for 20 doublings over 2 months and maintained expression of endothelial cell markers (CD31<sup>+</sup>VE-cadherin<sup>+</sup>CD34<sup>-</sup>). These cells exhibited uptake of acetylated low-density lipoprotein and formed tube-like structures when cultured on Matrigel. These endothelial cells also responded to TNF- $\alpha$  treatment by increasing ICAM-1 expression and maintained a dynamic barrier, responding to VEGF and cAMP analog by increasing or decreasing dextran permeability, respectively. Our findings demonstrate efficient and reproducible endothelial progenitor and endothelial differentiation of hPSCs by GSK3 inhibition in the absence of exogenous growth factor stimulation.

## EXPERIMENTAL PROCEDURES

### Maintenance of hPSCs

Transgene and vector free human iPSCs (19-9-11, 19-9-7, 6-9-9) (Yu et al., 2009) and hESCs (H1, H13, H14) (Thomson et al., 1998) were



**Figure 7. Characterization of Endothelial Cells Derived from hPSCs**

(A) 19-9-11 iPSCs were differentiated as illustrated in Figure 3A using LaSR basal medium. At day 5, CD34<sup>+</sup> cells were enriched and cultured in endothelial medium on laminin-coated plates. At different time points, the cell numbers were counted.

(B–D) The purified day 60 endothelial cells were immunostained with VE-cadherin and CD31 (B) and tested for tube-forming ability upon VEGF treatment (C) and the ability to uptake AcLDL (D).

(E) Flow cytometry analysis of surface protein expression of ICAM-1 of untreated cells or cells treated with 10 ng/ml TNF- $\alpha$  for 16 hr.

(F and G) Barrier phenotype of the hPSC-derived endothelial cells. Endothelial cells were differentiated as illustrated in Figure 3A using LaSR basal medium and then CD34<sup>+</sup> cells were enriched by MACS and cultured on laminin in endothelial cell medium. After 10 days in culture, the endothelial cells were seeded on collagen/fibronectin coated transwell filters and maintained in endothelial SFM. Barrier function was assessed by measuring TEER 48 hr after seeding. Next, cells were treated with endothelial SFM containing 100 ng/ml VEGF or 10  $\mu$ M oME. In (F), TEER was measured as a function of time, and normalized to the initial TEER value ( $36.7 \pm 4.3 \Omega\text{cm}^2$ ). In (G), TEER and fluorescent dextran permeability were measured 24 hr after plating. \*\* $p < 0.005$ , VEGF (or oME) versus control; t test.

Data are represented as mean  $\pm$  SEM of at least three independent replicates. See also Figure S5.

maintained on Matrigel (BD Biosciences)-coated plates (Corning) in mTeSR1 medium (STEMCELL Technologies) according to a previously published method (Lian et al., 2013a).

**Endothelial Progenitor Differentiation via Modulation of Canonical WNT Signaling**

hPSCs maintained on a Matrigel-coated surface in mTeSR1 were dissociated into single cells with Accutase (Life Technologies) at 37°C for 5 min and then seeded onto a Matrigel-coated cell culture dish at 50,000 cell/cm<sup>2</sup> in mTeSR1 supplemented with 5  $\mu$ M ROCK inhibitor Y-27632 (Selleckchem) (day -3) for 24 hr. Cells were then cultured in mTeSR1, changed daily. At day 0, cells were treated with 6–10  $\mu$ M CHIR99021 (Selleckchem) for 2 days in LaSR basal medium, which consists of Advanced DMEM/F12, 2.5 mM GlutaMAX, and 60  $\mu$ g/ml ascorbic acid (Sigma, A8960). After 2 days, CHIR99021-containing medium was aspirated and cells were main-

tained in LaSR basal medium without CHIR99021 for 3–4 additional days. PD0325901 was purchased from Tocris Bioscience.

**Differentiation of CD34<sup>+</sup> Cells to Endothelial Cells**

Day 5 differentiated populations were dissociated with Accutase for 10 min and purified with an EasySep Magnet kit (STEMCELL Technologies) using a CD34 antibody according to the manufacturer’s instructions. The purified CD34<sup>+</sup> cells were plated on collagen-IV-coated dishes (BD BioCoat) in EGM-2 medium (Lonza) and split every 4–5 days with Accutase.

**Differentiation of CD34<sup>+</sup> Cells to Smooth Muscle Cells**

Day 5 differentiated populations were dissociated with Accutase for 10 min and purified with an EasySep Magnet kit (STEMCELL Technologies) using a CD34 antibody according to the manufacturer’s instructions. The purified CD34<sup>+</sup> cells were plated on



collagen-IV-coated dishes (BD BioCoat) in SmGM-2 medium (Lonza) and split every 4–5 days with Accutase.

### Vascular Tube Formation Assay

To assess the formation of capillary structures,  $1 \times 10^5$  endothelial cells in 0.4 ml EGM-2 medium (Lonza) supplemented with 50 ng/ml VEGF (R&D Systems) were plated into one well of 24-well tissue culture plate precoated with 250  $\mu$ l Matrigel (BD Bioscience). Tube formation was observed by light microscopy after 24 hr of incubation.

### RT-PCR and Quantitative RT-PCR

Total RNA was prepared with the RNeasy mini kit (QIAGEN) and treated with DNase (QIAGEN). One microgram RNA was reverse transcribed into cDNA via Oligo (dT) with Superscript III Reverse Transcriptase (Invitrogen). Real-time quantitative PCR was done in triplicate with iQSYBR Green SuperMix (Bio-Rad). RT-PCR was performed with Gotaq Master Mix (Promega) and then subjected to 2% agarose gel electrophoresis. *ACTB* was used as an endogenous housekeeping control. PCR primer sequences are provided in the [Supplemental Experimental Procedures](#).

### Flow Cytometry

Cells were dissociated into single cells with Accutase for 10 min and then fixed with 1% paraformaldehyde for 20 min at room temperature and stained with primary and secondary antibodies ([Supplemental Experimental Procedures](#)) in PBS plus 0.1% Triton X-100 and 0.5% BSA. Data were collected on a FACSCaliber flow cytometer (Beckton Dickinson) and analyzed using FlowJo. FACS gating was based on the corresponding isotype antibody control.

### Immunostaining

Cells were fixed with 4% paraformaldehyde for 15 min at room temperature and then stained with primary and secondary antibodies ([Supplemental Experimental Procedures](#)) in PBS plus 0.4% Triton X-100 and 5% nonfat dry milk (Bio-Rad). Nuclei were stained with Gold antifade Reagent with DAPI (Invitrogen). An epifluorescence microscope (Leica DM IRB) with a QImaging Retiga 4000R camera was used for imaging analysis.

### Western Blot Analysis

Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Pierce) in the presence of Halt Protease and Phosphatase Inhibitor Cocktail (Pierce). Proteins were separated by 10% Tris-Glycine SDS/PAGE (Invitrogen) under denaturing conditions and transferred to a nitrocellulose membrane. After blocking with 5% dried milk in TBST, the membrane was incubated with primary antibody overnight at 4°C. The membrane was then washed, incubated with an anti-mouse/rabbit peroxidase-conjugated secondary antibody ([Supplemental Experimental Procedures](#)) at room temperature for 1 hr, and developed by SuperSignal chemiluminescence (Pierce).

### Monolayer Integrity

Purified CD31<sup>+</sup> endothelial cells were seeded on 12-well plate size 0.4  $\mu$ m porous polystyrene membrane inserts (Transwells, Corning) coated with a 0.4 mg/ml collagen IV and 0.1 mg/ml fibro-

nectin mixture at a density of 250,000 cells/insert. Cells were maintained in endothelial cell serum-free medium (SFM) (Life Technologies) for 48 hr prior to addition 0.5 ml and 1.5 ml of endothelial SFM at the apical and basolateral chambers respectively. Barrier tightness was assessed by measurement of transendothelial electrical resistance (TEER) using aEVOM STX2 electrode system (World Precision Instruments) before medium replacement. Baseline resistance values served to normalize subsequent TEER measurements. Cells were treated with either 100 ng/ml vascular endothelial growth factor (VEGF) or 10  $\mu$ M 8-(4-chlorophenylthio)-2'-O-Me-cAMP (oMe). TEER measurements were acquired every 2 hr, with the exception of oME-treated cells. After 24 hr of treatment, vascular permeability was assessed by replacing the medium in the top chamber with 500  $\mu$ l of 1  $\mu$ M 40 kDa fluorescein isothiocyanate-dextran (Sigma-Aldrich) dissolved in endothelium SFM. At 15, 30, 45, and 60 min, 150  $\mu$ l aliquots were taken from the basolateral chamber and replaced with warm endothelial SFM. Cell permeability was calculated following the *Pe* clearance method ([Calabria et al., 2006](#); [Jones and Shusta, 2007](#)).

### Statistics

Data are presented as mean  $\pm$  SEM. Statistical significance was determined by Student's t test (two-tail) between two groups.  $p < 0.05$  was considered statistically significant.

### SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and five figures and can be found with this article online at <http://dx.doi.org/10.1016/j.stemcr.2014.09.005>.

### AUTHOR CONTRIBUTIONS

X.L. and X.B. conceived, performed, and interpreted most of the experiments and wrote the manuscript; J.L., Y.W., W.D., and K.K.D. assisted in endothelial differentiation and characterization experiments; A.A. performed and interpreted endothelial characterization experiments; E.V.S. provided experimental advice and funding support; S.P.P. conceived experiments, provided experimental advice, wrote the manuscript, and provided funding support.

### ACKNOWLEDGMENTS

This work was supported by NIH grants R01 EB007534 (S.P.P.) and R21 NS085351 (S.P.P. and E.V.S.) and by funding from Takeda Pharmaceuticals (S.P.P. and E.V.S.). K.K.D. was funded in part by an NIH Chemistry Biology Interface Training Grant (NIGMS T32 GM008505).

Received: March 9, 2014

Revised: September 5, 2014

Accepted: September 8, 2014

Published: October 9, 2014

### REFERENCES

Adams, W.J., Zhang, Y., Cloutier, J., Kuchimanchi, P., Newton, G., Sehrawat, S., Aird, W.C., Mayadas, T.N., Lusinskas, F.W., and García-Cardena, G. (2013). Functional vascular endothelium derived



- from human induced pluripotent stem cells. *Stem Cell Rep.* *1*, 105–113.
- Ashton, R.S., Keung, A.J., Peltier, J., and Schaffer, D.V. (2011). Progress and prospects for stem cell engineering. *Annu. Rev. Chem. Biomol. Eng.* *2*, 479–502.
- Bai, H., Gao, Y., Arzigian, M., Wojchowski, D.M., Wu, W.S., and Wang, Z.Z. (2010). BMP4 regulates vascular progenitor development in human embryonic stem cells through a Smad-dependent pathway. *J. Cell. Biochem.* *109*, 363–374.
- Boyle, E.M., Jr., Lille, S.T., Allaire, E., Clowes, A.W., and Verrier, E.D. (1997). Endothelial cell injury in cardiovascular surgery: atherosclerosis. *Ann. Thorac. Surg.* *63*, 885–894.
- Burridge, P.W., Keller, G., Gold, J.D., and Wu, J.C. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. *Cell Stem Cell* *10*, 16–28.
- Cai, J., Schleidt, S., Pelta-Heller, J., Hutchings, D., Cannarsa, G., and Iacovitti, L. (2013). BMP and TGF- $\beta$  pathway mediators are critical upstream regulators of Wnt signaling during midbrain dopamine differentiation in human pluripotent stem cells. *Dev. Biol.* *376*, 62–73.
- Calabria, A.R., Weidenfeller, C., Jones, A.R., de Vries, H.E., and Shusta, E.V. (2006). Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. *J. Neurochem.* *97*, 922–933.
- Chanda, B., Ditadi, A., Iscove, N.N., and Keller, G. (2013). Retinoic acid signaling is essential for embryonic hematopoietic stem cell development. *Cell* *155*, 215–227.
- Costa, M., Sourris, K., Lim, S.M., Yu, Q.C., Hirst, C.E., Parkington, H.C., Jokubaitis, V.J., Dear, A.E., Liu, H.B., Micallef, S.J., et al. (2013). Derivation of endothelial cells from human embryonic stem cells in fully defined medium enables identification of lysophosphatidic acid and platelet activating factor as regulators of eNOS localization. *Stem Cell Res. (Amst.)* *10*, 103–117.
- Davis, R.P., Ng, E.S., Costa, M., Mossman, A.K., Sourris, K., Elefanty, A.G., and Stanley, E.G. (2008). Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. *Blood* *111*, 1876–1884.
- Di Bernardini, E., Campagnolo, P., Margariti, A., Zampetaki, A., Karamariti, E., Hu, Y., and Xu, Q. (2013). Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor beta2 (TGF-beta2) pathways. *J Biol Chem.*
- Gage, B.K., Webber, T.D., and Kieffer, T.J. (2013). Initial cell seeding density influences pancreatic endocrine development during in vitro differentiation of human embryonic stem cells. *PLoS ONE* *8*, e82076.
- Grigoriadis, A.E., Kennedy, M., Bozec, A., Brunton, F., Stenbeck, G., Park, I.H., Wagner, E.F., and Keller, G.M. (2010). Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. *Blood* *115*, 2769–2776.
- Hergovich, A., and Hemmings, B.A. (2010). TAZ-mediated cross-talk between Wnt and Hippo signaling. *Dev. Cell* *18*, 508–509.
- Huber, T.L., Kouskoff, V., Fehling, H.J., Palis, J., and Keller, G. (2004). Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. *Nature* *432*, 625–630.
- James, D., Nam, H.S., Seandel, M., Nolan, D., Janovitz, T., Tomishima, M., Studer, L., Lee, G., Lyden, D., Benezra, R., et al. (2010). Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent. *Nat. Biotechnol.* *28*, 161–166.
- Jones, A.R., and Shusta, E.V. (2007). Blood-brain barrier transport of therapeutics via receptor-mediation. *Pharm. Res.* *24*, 1759–1771.
- Kane, N.M., Meloni, M., Spencer, H.L., Craig, M.A., Strehl, R., Milligan, G., Houslay, M.D., Mountford, J.C., Emanuelli, C., and Baker, A.H. (2010). Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. *Arterioscler. Thromb. Vasc. Biol.* *30*, 1389–1397.
- Kaupisch, A., Kennedy, L., Stelmanis, V., Tye, B., Kane, N.M., Mountford, J.C., Courtney, A., and Baker, A.H. (2012). Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. *J. Cardiovasc. Transl. Res.* *5*, 605–617.
- Kennedy, M., Firpo, M., Choi, K., Wall, C., Robertson, S., Kabrun, N., and Keller, G. (1997). A common precursor for primitive erythropoiesis and definitive haematopoiesis. *Nature* *386*, 488–493.
- Kinney, M.A., Hookway, T.A., Wang, Y., and McDevitt, T.C. (2014). Engineering three-dimensional stem cell morphogenesis for the development of tissue models and scalable regenerative therapeutics. *Ann. Biomed. Eng.* *42*, 352–367.
- Kusuma, S., Shen, Y.I., Hanjaya-Putra, D., Mali, P., Cheng, L., and Gerecht, S. (2013). Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix. *Proc. Natl. Acad. Sci. USA* *110*, 12601–12606.
- Levenberg, S., Golub, J.S., Amit, M., Itskovitz-Eldor, J., and Langer, R. (2002). Endothelial cells derived from human embryonic stem cells. *Proc. Natl. Acad. Sci. USA* *99*, 4391–4396.
- Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarin, S.M., Raval, K.K., Zhang, J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc. Natl. Acad. Sci. USA* *109*, E1848–E1857.
- Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., Hsiao, C., Kamp, T.J., and Palecek, S.P. (2013a). Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/ $\beta$ -catenin signaling under fully defined conditions. *Nat. Protoc.* *8*, 162–175.
- Lian, X., Zhang, J., Zhu, K., Kamp, T.J., and Palecek, S.P. (2013b). Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition. *Stem Cells* *31*, 447–457.
- Liu, X., Ye, R., Yan, T., Yu, S.P., Wei, L., Xu, G., Fan, X., Jiang, Y., Stetler, R.A., and Chen, J. (2014). Cell based therapies for ischemic stroke: From basic science to bedside. *Prog. Neurobiol.*



- Lu, S.J., Feng, Q., Caballero, S., Chen, Y., Moore, M.A., Grant, M.B., and Lanza, R. (2007). Generation of functional hemangioblasts from human embryonic stem cells. *Nat. Methods* 4, 501–509.
- Marchand, M., Anderson, E.K., Phadnis, S.M., Longaker, M.T., Cooke, J.P., Chen, B., and Reijo Pera, R.A. (2014). Concurrent Generation of Functional Smooth Muscle and Endothelial Cells via a Vascular Progenitor. *Stem Cells Transl. Med.* 3, 91–97.
- Murry, C.E., and Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. *Cell* 132, 661–680.
- Nakanishi, M., Kurisaki, A., Hayashi, Y., Warashina, M., Ishiura, S., Kusuda-Furue, M., and Asashima, M. (2009). Directed induction of anterior and posterior primitive streak by Wnt from embryonic stem cells cultured in a chemically defined serum-free medium. *FASEB J.* 23, 114–122.
- Orlova, V.V., Drabsch, Y., Freund, C., Petrus-Reurer, S., van den Hil, F.E., Muenthaisong, S., Dijke, P.T., and Mummery, C.L. (2014). Functionality of endothelial cells and pericytes from human pluripotent stem cells demonstrated in cultured vascular plexus and zebrafish xenografts. *Arterioscler. Thromb. Vasc. Biol.* 34, 177–186.
- Robey, T.E., Saiget, M.K., Reinecke, H., and Murry, C.E. (2008). Systems approaches to preventing transplanted cell death in cardiac repair. *J. Mol. Cell. Cardiol.* 45, 567–581.
- Rufaihah, A.J., Huang, N.F., Jamé, S., Lee, J.C., Nguyen, H.N., Byers, B., De, A., Okogbaa, J., Rollins, M., Reijo-Pera, R., et al. (2011). Endothelial cells derived from human iPSCs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. *Arterioscler. Thromb. Vasc. Biol.* 31, e72–e79.
- Rufaihah, A.J., Huang, N.F., Kim, J., Herold, J., Volz, K.S., Park, T.S., Lee, J.C., Zambidis, E.T., Reijo-Pera, R., and Cooke, J.P. (2013). Human induced pluripotent stem cell-derived endothelial cells exhibit functional heterogeneity. *Am. J. Transl. Res.* 5, 21–35.
- Samuel, R., Daheron, L., Liao, S., Vardam, T., Kamoun, W.S., Batista, A., Buecker, C., Schäfer, R., Han, X., Au, P., et al. (2013). Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. *Proc. Natl. Acad. Sci. USA* 110, 12774–12779.
- Selekman, J.A., Grundl, N.J., Kolz, J.M., and Palecek, S.P. (2013). Efficient generation of functional epithelial and epidermal cells from human pluripotent stem cells under defined conditions. *Tissue Eng. Part C Methods* 19, 949–960.
- Slukvin, I.I. (2013). Deciphering the hierarchy of angiohematopoietic progenitors from human pluripotent stem cells. *Cell Cycle* 12, 720–727.
- Song, S.H., Jung, W., Kim, K.L., Hong, W., Kim, H.O., Lee, K.A., Lee, K.Y., and Suh, W. (2013). Distinct transcriptional profiles of angioblasts derived from human embryonic stem cells. *Exp. Cell Res.* 319, 1136–1145.
- Stulberg, M.J., Lin, A., Zhao, H., and Holley, S.A. (2012). Crosstalk between Fgf and Wnt signaling in the zebrafish tailbud. *Dev. Biol.* 369, 298–307.
- Takizawa-Shirasawa, S., Yoshie, S., Yue, F., Mogi, A., Yokoyama, T., Tomotsune, D., and Sasaki, K. (2013). FGF7 and cell density are required for final differentiation of pancreatic amylase-positive cells from human ES cells. *Cell Tissue Res.* 354, 751–759.
- Tan, J.Y., Sriram, G., Rufaihah, A.J., Neoh, K.G., and Cao, T. (2013). Efficient derivation of lateral plate and paraxial mesoderm subtypes from human embryonic stem cells through GSKi-mediated differentiation. *Stem Cells Dev.* 22, 1893–1906.
- Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145–1147.
- van der Meer, A.D., Orlova, V.V., ten Dijke, P., van den Berg, A., and Mummery, C.L. (2013). Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. *Lab Chip* 13, 3562–3568.
- Vodyanik, M.A., Yu, J., Zhang, X., Tian, S., Stewart, R., Thomson, J.A., and Slukvin, I.I. (2010). A mesoderm-derived precursor for mesenchymal stem and endothelial cells. *Cell Stem Cell* 7, 718–729.
- Wang, L., Li, L., Shojaei, F., Levac, K., Cerdan, C., Menendez, P., Martin, T., Rouleau, A., and Bhatia, M. (2004). Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. *Immunity* 21, 31–41.
- Wang, Z.Z., Au, P., Chen, T., Shao, Y., Daheron, L.M., Bai, H., Arzigian, M., Fukumura, D., Jain, R.K., and Scadden, D.T. (2007). Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. *Nat. Biotechnol.* 25, 317–318.
- Wang, H.Y., Huang, Y.X., Qi, Y.F., Zhang, Y., Bao, Y.L., Sun, L.G., Zheng, L.H., Zhang, Y.W., Ma, Z.Q., and Li, Y.X. (2013). Mathematical models for the Notch and Wnt signaling pathways and the crosstalk between them during somitogenesis. *Theor. Biol. Med. Model.* 10, 27.
- Weiss, N., Miller, F., Cazaubon, S., and Couraud, P.O. (2009). The blood-brain barrier in brain homeostasis and neurological diseases. *Biochim. Biophys. Acta* 1788, 842–857.
- White, M.P., Rufaihah, A.J., Liu, L., Ghebremariam, Y.T., Ivey, K.N., Cooke, J.P., and Srivastava, D. (2013). Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. *Stem Cells* 31, 92–103.
- Wolfe, R.P., and Ahsan, T. (2013). Shear stress during early embryonic stem cell differentiation promotes hematopoietic and endothelial phenotypes. *Biotechnol. Bioeng.* 110, 1231–1242.
- Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I.I., and Thomson, J.A. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324, 797–801.
- Yu, P., Pan, G., Yu, J., and Thomson, J.A. (2011). FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. *Cell Stem Cell* 8, 326–334.
- Zambidis, E.T., Peault, B., Park, T.S., Bunz, F., and Civin, C.I. (2005). Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development. *Blood* 106, 860–870.


Stem Cell Reports, Volume 3

Supplemental Information


**Efficient Differentiation of Human Pluripotent  
Stem Cells to Endothelial Progenitors via  
Small-Molecule Activation of WNT Signaling**

Xiaojun Lian, Xiaoping Bao, Abraham Al-Ahmad, Jialu Liu, Yue Wu, Wentao Dong, Kaitlin K. Dunn, Eric V. Shusta, and Sean P. Palecek

## SUPPLEMENTAL FIGURES AND LEGENDS




**Figure S1.** Differentiation of H1 human embryonic stem cells to endothelial progenitors, related to Figure 1. H1 Human embryonic stem cells were cultured on Matrigel in LaSR basal medium containing 6  $\mu$ M CH for 2 days followed by another 3 days in Stem-Pro 34 medium. Flow cytometry analysis of CD34 and CD31, CD31 and CD144, CD31 and CD45 expression was performed after 5 days of differentiation.




**Figure S2.** Endothelial differentiation requires  $\beta$ -catenin expression, related to Figure 2. 19-9-11 ishcat iPSCs were cultured in LaSR basal medium containing 6  $\mu$ M CH and/or 2  $\mu$ g/ml doxycycline for 2 days. Flow cytometry analysis of brachyury expression was performed after 2 days of differentiation.







**E**




**F**



**Figure S3.** Differentiation of multiple hESC and iPSC lines to endothelial progenitors, related to Figure 5. Purified CD34<sup>+</sup> cells were generated as described in Fig. 5A from different hPSC lines: (A) hESC H13, (B) hESC H14, (C) iPSC 19-9-7 and (D) iPSC 6-9-9. Flow cytometry analysis of CD34 expression was performed before (left) and after (right) EasySep™ Human CD34 Positive Selection Kit. Single CD34<sup>+</sup> cells were cultured in a combined medium for 10 days (E, F). Immunostaining of (E) calponin and (F) VE-cadherin/vWF/SMA were performed.



**Figure S4.** Analysis of endothelial progenitor marker expression, related to Figure 6. Flow cytometry analysis of developmental markers (A) Tie-2, (B) CD117, (C) KDR, and (D) I-CAM1 in day 5 unsorted CD34+ endothelial progenitors were performed.



**Figure S5.** Analysis of endothelial marker expression in day 60 endothelial cells, related to Figure 7.

Flow cytometry analysis of VE-cadherin (A & B) and CD31 (C & D) expression in day 60 endothelial cells was performed. (A) and (C) are corresponding isotype controls.

## SUPPLEMENTAL EXPERIMENTAL PROCEDURES

### Primers for Q-PCR

<b>Genes</b>	<b>Sequences (5' - 3')</b>	<b>Size (bp)/Tm (°C)</b>
<i>OCT4</i>	<b>F:</b> CAGTGCCCGAAACCCACAC <b>R:</b> GGAGACCCAGCAGCCTCAAA	161/58
<i>SOX2</i>	<b>F:</b> CAAGATGCACAACCTCGGAGA <b>R:</b> GTTCATGTGCGCGTAACTGT	300/58
<i>MIXL1</i>	<b>F:</b> CAGAGTGGGAAATCCTTCCA <b>R:</b> TGAGTCCAGCTTTGAACCAA	231/58
<i>CD31</i>	<b>F:</b> GCTGACCCTTCTGCTCTGTT <b>R:</b> TGAGAGGTGGTGCTGACATC	238/55
<i>CD34</i>	<b>F:</b> CCTAAGTGACATCAAGGCAGAA <b>R:</b> GCAAGGAGCAGGGAGCATA	201/55
<i>ACTB</i>	<b>F:</b> CCTGAACCCTAAGGCCAACCG <b>R:</b> GTCATAGCTCTTCTCCAGGG	400/58
<i>GAPDH</i>	<b>F:</b> GTGGACCTGACCTGCCGTCT <b>R:</b> GGAGGAGTGGGTGTCGCTGT	152/58
<i>T</i>	<b>F:</b> AAGAAGGAAATGCAGCCTCA <b>R:</b> TACTGCAGGTGTGAGCAAGG	101/58
<i>CTNNB1</i>	<b>F:</b> CCCCTAATGTCCAGCGTTT <b>R:</b> AACGCATGATAGCGTGTCTG	217/58

Antibodies for immunostaining (IS), western blotting (WB) and flow cytometry (FC)

Antibody		Application
CD31-APC	Miltenyi Biotec, mouse IgG1, Clone: AC128 Cat. no: 130-092-652	1:50 (FC)
CD34-FITC	Miltenyi Biotec, mouse IgG2a, Clone: AC136 Cat. no: 130-081-001	1:50 (FC)
Brachyury	R&D Polyclonal Ab, GoatIgG Clone: AF2085	1:100 (FC) 1:1000 (WB)
VE-cadherin	Santa Cruz, mouse IgG1, Clone: F-8 sc9989	1:100 (IS) 1:1000 (WB)
OCT-3/4	Santa Cruz, Mouse IgG2b Clone: C-10 sc-5279	1:100 (IS) 1:1000 (WB)
SMMHC	Abcam 82541, RabbitIgG, Cat. no: 82541	1:800 (IS)
Actin, smooth muscle	Thermo Scientific, mouse IgG2a/ $\kappa$ Clone: 1A4 MS-113-P	1:100 (IS)
CD117 (c-kit)	BD Pharmingen, mouse IgG1/ $\kappa$ Clone: YB5.B8 Cat. no:555713	1:200 (IS)
TIE-2	Santa Cruz, rabbit IgG, Clone: H-176 sc9026	1:200 (IS)
KDR	Santa Cruz, mouse IgG1, Clone: A-3 sc6251	1:200 (IS)
vWF	Dako, rabbit IgG, Cat. no: A008202-5	1:500 (IS)
ICAM-1 (CD54)	DSHB, mouse IgG1, P2A4	1:30 (IS)
Calponin	Abcam, Mouse IgG1, Clone: CALP Cat. no: ab700	1:200 (IS)
$\beta$ -Actin	Cell Signaling Technology, Rabbit mAb (HRP Conjugate), 13E5,5125S	1:5000 (WB)
goat anti-mouse IgG- HRP	Santa Cruz, sc-2005	1:3000 (WB)